Non-invasive ventilation (NIV) is commonly offered to people with Motor Neurone Disease (MND) who have breathing difficulties. It improves their quality of life and can prolong life by 6 months or more. It is initially used at night and typically set up during a hospital admission. By the time that they develop respiratory failure and need to start NIV, however, most patients require wheelchairs or have other significant health problems. Repeated travel to hospitals is increasingly difficult with increasing disability. It is possible to start and monitor NIV treatment at home. This may be more convenient for selected patients, though starting NIV is quite complex; it is not known if home treatment is as safe and effective as hospital-based treatment. To establish this, 60 patients with MND who have indications for NIV will be recruited. They will be randomly allocated to a home-based treatment (home NIV set up plus home visits supported by telemonitoring) or hospital-based care (inpatient NIV set up plus outpatient NIV monitoring) and followed up at 1, 4 and 7 months. Alongside measures of treatment effectiveness, assessment of patient and carer preferences, quality of life, and cost-effectiveness will be undertaken. In the additional qualitative part on this study, interviews with patients who took part in the main study and their carers will be conducted to understand in more depth their perspective on what makes for a good or bad experience with NIV, how the environment (home vs hospital) influences their NIV experience and what personal factors determine NIV use. Findings from the interviews will inform the design of a truly patient-centred NIV service.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Providing ventilation support through non-invasive means
Royal Paworth Hospital
Cambridge, United Kingdom
RECRUITINGControl of respiratory failure defined by daytime partial pressure of carbon dioxide (PaCO2)
Daytime PaCO2 measured by arterial puncture
Time frame: measured at 1,4,7 months following NIV initiation
Patients and carers experiences of starting and managing NIV, and factors that relate to NIV concordance and acceptance.
Semi-structured interview with patients and their carers
Time frame: measured at 4 weeks since starting NIV
NIV acceptance
Percent of patients using NIV for \>=4hrs/night
Time frame: 1 month
NIV concordance
NIV adherence (machine usage in hours/24hours)
Time frame: 1 , 4 and 7 months
Survival
Survival (in months)
Time frame: Survival since NIV initiation
Admissions
Number of additional planned and emergency hospital admissions
Time frame: Up to 7 months from initiation of NIV
NIV setting changes
Number of NIV setting changes required
Time frame: 1 , 4 and 7 months
Cost effectiveness
Absolute costs and costs in relation to quality-adjusted life-years (using EQ-5D)
Time frame: Up to 7 months from initiation of NIV
Nocturnal oximetry
time spent with oxygen saturation \<90%(TST90)
Time frame: 1,4,7 months
Other blood gas analysis measurements of hypoventilation
Bicarbonate
Time frame: 1,4,7 months
Quality of life assessment (EQ-5D-5L)
Measurement of quality of life using EQ-5D-5L questionnaire
Time frame: 1,4,7 ,months
Quality of life (SRI)
Quality of life measured using Severe Respiratory Insufficiency (SRI) questionnaire
Time frame: 1,4, 7 months
Quality of sleep
Sleep quality measured with Pittsburgh Sleep Quality Index (PSQI)
Time frame: 1,4,7 ,months
Satisfaction with NIV and healthcare interactions
Satisfaction with NIV and healthcare interactions measured with a visual analogue scale
Time frame: 7 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.